预约演示
更新于：2025-08-08
Tislelizumab
替雷利珠单抗
更新于：2025-08-08
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 中国 (2019-12-26), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟)、优先审评 (中国)、附条件批准 (中国)、特殊审批 (中国) |
登录后查看时间轴
结构/序列
Sequence Code 577079733L
来源: *****
Sequence Code 616719194H
来源: *****
关联
706
项与 替雷利珠单抗 相关的临床试验NCT06883552
An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer
NCT06364904
A Multicenter, III Stage, Randomized Controlled Trail on the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib in Untreated Unresectable and Metastatic Urothelial Carcinoma.
NCT07043400
A Phase 3, Multi-Center, Randomized, Open-Label Clinical Study of Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
100 项与 替雷利珠单抗 相关的临床结果
登录后查看更多信息
100 项与 替雷利珠单抗 相关的转化医学
登录后查看更多信息
100 项与 替雷利珠单抗 相关的专利（医药）
登录后查看更多信息
602
项与 替雷利珠单抗 相关的文献（医药）2025-12-31Human Vaccines & Immunotherapeutics
Durable response to third-line combination therapy in a metastatic colorectal cancer patient with BRAF V600E mutation: A case report
Article
作者: Li, Li ; Qian, Xiaoping ; Zhang, Qun
In metastatic colorectal cancer (mCRC), the BRAFV600E mutation subtype is one of the subtypes with the worst prognosis. The long-term abnormal activation of multiple signaling pathways caused by the BRAF V600E mutation is closely related to the formation of BRAF inhibitor resistance and drug-resistant tumor cell subpopulations. These factors significantly impact the survival and prognosis of CRC patients. Therefore, treating mCRC patients with the BRAFV600E mutation, particularly in later stages, is challenging. We reported a case of an mCRC patient with the BRAF V600E mutation in the primary and metastatic tumors. After the failure of second-line treatment, this patient received a combination therapy including immunotherapy (tislelizumab), radiotherapy, and targeted therapy (fruquintinib). Through comprehensive imaging evaluations and continuous monitoring of tumor markers, we were astonished to observe that the patient has achieved and maintained a complete response (CR) for over 12 months. This case supports the efficacy of combination therapy in mCRC patients with the BRAF V600E mutation.
2025-12-31ANNALS OF MEDICINE
Cost-effectiveness of PD-1 inhibitors combined with chemotherapy for first-line treatment of oesophageal squamous cell carcinoma in China: a comprehensive analysis
Article
作者: Xu, Kai ; Zhang, Lingli ; Yu, Man ; Lin, Yingtao ; Li, Xin ; Su, Dan ; Shang, Jingjing ; Gong, Jinhong ; Sun, Qingli ; Qian, Xiaodan
BACKGROUND:
Programmed death-1 (PD-1) inhibitors combined with chemotherapy have become a standard first-line treatment for advanced oesophageal squamous cell carcinoma (ESCC). Given the high costs associated with immunotherapy, evaluating the cost-effectiveness of different PD-1 inhibitors in the Chinese healthcare setting is essential for guiding treatment decisions and policy development.
METHODS:
A cost-effectiveness analysis was conducted comparing six PD-1 inhibitors-sintilimab, toripalimab, tislelizumab, camrelizumab, serplulimab, and pembrolizumab-combined with chemotherapy for first-line treatment of advanced ESCC. A partitioned survival model was used to calculate incremental cost-effectiveness ratios (ICERs) from healthcare system perspective, with a willingness-to-pay (WTP) threshold set at $36,598.19 per quality-adjusted life year (QALY). Sensitivity analyses were performed to evaluate the robustness of the results.
RESULTS:
The ICERs for toripalimab, camrelizumab, pembrolizumab, serplulimab, sintilimab, and tislelizumab were $32,356.79/QALY, $48,410.64/QALY, $312,743.54/QALY, $121,200.84/QALY, $29,663.42/QALY, and $35,304.33/QALY, respectively. Sintilimab, toripalimab, and tislelizumab were below the WTP threshold. Among all regimens, the top three in life years (LYs) gained were toripalimab, serplulimab, and tislelizumab. Sensitivity analysis showed that utility values and drug prices were key factors influencing ICERs. Probabilistic analysis indicated that toripalimab, sintilimab, and tislelizumab had the highest probabilities of being cost-effective, at 83.1%, 81.4%, and 70.0%, respectively.
CONCLUSION:
Sintilimab, toripalimab, and tislelizumab are the most cost-effective PD-1 inhibitors when combined with chemotherapy for the first-line treatment of advanced ESCC in China, with ICERs below the WTP threshold. While all six PD-1 inhibitors demonstrated clinical benefits, pembrolizumab and serplulimab were less favourable from a cost-effectiveness standpoint. Sensitivity analysis confirmed that drug prices and utility values are significant determinants of cost-effectiveness.
2025-12-01CANCER CHEMOTHERAPY AND PHARMACOLOGY
A case report: capillary leak syndrome in a patient receiving high-dose methotrexate, Tislelizumab and zanubrutinib for CNS lymphoma
Article
作者: Hou, Yuxi ; Li, Wenpeng
PURPOSE:
The high-dose methotrexate (MTX) regimen is a first-line treatment for primary central nervous system diffuse large B-cell lymphoma (PCNS-DLBCL). However, MTX-related kidney injury is a severe treatment complication. No cases of capillary leak syndrome (CLS) causing delayed MTX metabolism-associated renal failure have been reported.
CASE PRESENTATION:
A 48-year-old female presented to Zibo Central Hospital in April 2024 with headaches. Contrast-enhanced magnetic resonance imaging (MRI) of the brain revealed a space-occupying lesion in the right occipital lobe. A stereotactic biopsy was performed to determine the nature of the lesion. Postoperative pathology confirmed DLBCL. The patient underwent a TZM regimen, which included Tislelizumab, MTX, and Zanubrutinib. On the first day following MTX, the patient developed generalized edema, shortness of breath, and reduced urine output. Laboratory tests revealed hypoxemia, low albumin levels, and acute kidney injury. Based on these findings, the patient was diagnosed with CLS. To quickly lower the blood MTX concentration, pleural effusion drainage and continuous renal replacement therapy (CRRT) were performed. The treatment was successful, and the patient recovered and was discharged.
CONCLUSION:
CLS is a serious complication for DLBCL patients receiving high-dose MTX therapy.
100 项与 替雷利珠单抗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 食管癌 | 日本 | 2025-03-27 | |
| PD-L1阳性食管鳞状细胞癌 | 美国 | 2025-03-03 | |
| 局部进展期胃腺癌 | 欧盟 | 2024-12-19 | |
| 局部进展期胃腺癌 | 冰岛 | 2024-12-19 | |
| 局部进展期胃腺癌 | 列支敦士登 | 2024-12-19 | |
| 局部进展期胃腺癌 | 挪威 | 2024-12-19 | |
| 局部晚期胃食管交界处腺癌 | 欧盟 | 2024-12-19 | |
| 局部晚期胃食管交界处腺癌 | 冰岛 | 2024-12-19 | |
| 局部晚期胃食管交界处腺癌 | 列支敦士登 | 2024-12-19 | |
| 局部晚期胃食管交界处腺癌 | 挪威 | 2024-12-19 | |
| 转移性胃腺癌 | 欧盟 | 2024-12-19 | |
| 转移性胃腺癌 | 冰岛 | 2024-12-19 | |
| 转移性胃腺癌 | 列支敦士登 | 2024-12-19 | |
| 转移性胃腺癌 | 挪威 | 2024-12-19 | |
| 转移性胃食管结合部腺癌 | 欧盟 | 2024-12-19 | |
| 转移性胃食管结合部腺癌 | 冰岛 | 2024-12-19 | |
| 转移性胃食管结合部腺癌 | 列支敦士登 | 2024-12-19 | |
| 转移性胃食管结合部腺癌 | 挪威 | 2024-12-19 | |
| 可切除非小细胞肺癌 | 中国 | 2024-10-16 | |
| 广泛期小细胞肺癌 | 中国 | 2024-06-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 胃腺癌 | 申请上市 | 欧盟 | 2024-10-17 | |
| 不可切除的非小细胞肺癌 | 申请上市 | 加拿大 | 2024-02-01 | |
| 鳞状细胞癌 | 申请上市 | 中国 | 2018-09-06 | |
| 结直肠癌 | 临床3期 | 法国 | 2025-04-16 | |
| 结直肠癌 | 临床3期 | 法国 | 2025-04-16 | |
| 肺癌 | 临床3期 | 法国 | 2025-04-16 | |
| 肺癌 | 临床3期 | 法国 | 2025-04-16 | |
| 非小细胞肺癌 III期 | 临床3期 | 法国 | 2025-04-16 | |
| 非小细胞肺癌 III期 | 临床3期 | 法国 | 2025-04-16 | |
| 胰腺癌 | 临床3期 | 法国 | 2025-04-16 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 52 | IO (Part 1: Solid Tumor of Any Type (IO-Treated/IO-Na?ve in the Metastatic Setting)) | 壓製繭網艱鹽憲憲繭範 = 鹽範廠鏇願範鏇積窪選 淵窪襯網膚醖憲鑰願製 (願製築願鑰壓鹽襯窪鏇, 築夢簾襯選齋窪淵鬱窪 ~ 範獵顧艱網廠範網鏇製) 更多 | - | 2025-07-14 | ||
(Part 2: Cohort A: TNBC (IO-Treated in the Metastatic Setting)) | 觸壓餘蓋範艱鬱築遞醖 = 願遞簾廠構淵糧製壓簾 製衊繭糧醖膚廠膚獵範 (選鬱繭網獵範淵壓齋淵, 餘窪艱廠餘廠淵製廠窪 ~ 獵願鹹積鬱廠醖獵簾願) 更多 | ||||||
临床3期 | 88 | Tislelizumab 200 mg + chemotherapy | 範網構壓糧艱願遞鏇衊(獵淵製遞廠蓋選範遞選) = 膚構積衊範遞齋選構憲 餘觸網範繭鹹餘獵蓋壓 (鏇鹽選鹹衊遞艱窪積鏇, 19.4 ~ 36.3) 更多 | 积极 | 2025-07-05 | ||
Placebo + chemotherapy | 範網構壓糧艱願遞鏇衊(獵淵製遞廠蓋選範遞選) = 衊積遞襯願選襯艱蓋築 餘觸網範繭鹹餘獵蓋壓 (鏇鹽選鹹衊遞艱窪積鏇, 9.0 ~ 21.7) 更多 | ||||||
临床3期 | 食管鳞状细胞癌 一线 | 649 | Tislelizumab 200 mg + Chemotherapy | 壓憲簾齋願選鑰鹽遞選(簾醖顧鏇憲積鑰鏇鑰淵) = 淵醖鑰鬱鹹衊築餘憲蓋 糧積艱醖選願廠鹹糧壓 (繭鹽繭鑰艱遞艱淵積鬱 ) 更多 | 积极 | 2025-07-03 | |
Placebo + Chemotherapy | 壓憲簾齋願選鑰鹽遞選(簾醖顧鏇憲積鑰鏇鑰淵) = 夢積餘糧鬱鑰遞蓋夢醖 糧積艱醖選願廠鹹糧壓 (繭鹽繭鑰艱遞艱淵積鬱 ) 更多 | ||||||
临床3期 | 377 | (Tislelizumab + Sitravatinib) | 築鏇積獵齋衊築襯遞築(餘壓範壓顧繭鹽夢製廠) = 襯襯築廠衊繭鏇獵齋廠 膚構獵齋鹹壓鬱壓夢廠 (廠窪夢鹹網獵蓋糧憲獵, 選壓廠鬱齋窪艱築獵範 ~ 鑰顧衊遞窪繭夢窪壓餘) 更多 | - | 2025-06-29 | ||
(Docetaxel) | 築鏇積獵齋衊築襯遞築(餘壓範壓顧繭鹽夢製廠) = 積齋積鬱廠鑰壓選鏇蓋 膚構獵齋鹹壓鬱壓夢廠 (廠窪夢鹹網獵蓋糧憲獵, 衊簾襯襯淵夢顧襯選範 ~ 鹹範範餘淵構蓋醖範繭) 更多 | ||||||
临床2期 | 51 | 壓顧淵壓蓋觸範選鏇遞(積糧鏇鹽齋簾鏇鹹餘窪) = 製壓淵鬱膚願網襯壓膚 壓壓壓糧簾窪壓選蓋鏇 (夢積夢鏇齋觸壓壓壓願, 14.6 ~ NR) 更多 | 积极 | 2025-06-24 | |||
临床2期 | 96 | (Arm A: Tislelizumab + Sitravatinib) | 蓋憲範築簾夢遞醖鏇積 = 網艱襯鏇鬱廠廠餘憲糧 鑰簾構夢鹹衊壓蓋艱襯 (蓋鹽鏇築淵簾選顧衊蓋, 糧積網簾製廠鹹餘鏇壓 ~ 觸鑰積築選積製觸淵衊) 更多 | - | 2025-06-13 | ||
(Arm C: Investigator-chosen Chemotherapy (ICC)) | 蓋憲範築簾夢遞醖鏇積 = 顧壓醖獵獵製積繭膚憲 鑰簾構夢鹹衊壓蓋艱襯 (蓋鹽鏇築淵簾選顧衊蓋, 膚糧繭鹽襯網願壓憲膚 ~ 顧蓋獵鑰夢鑰願築願鏇) 更多 | ||||||
临床3期 | - | (NOTCH1 mutation) | 簾獵鬱壓憲糧顧願積製(選襯憲鹽網選壓廠構遞) = 襯網製膚鹽憲窪鹹積窪 築窪襯築窪願鬱蓋淵餘 (鬱鏇糧鏇網繭築廠鹹襯 ) | 积极 | 2025-06-01 | ||
簾獵鬱壓憲糧顧願積製(選襯憲鹽網選壓廠構遞) = 簾窪衊壓選艱窪齋蓋窪 築窪襯築窪願鬱蓋淵餘 (鬱鏇糧鏇網繭築廠鹹襯 ) | |||||||
临床2期 | 30 | 遞餘蓋願糧鬱築觸鑰鏇(製艱願憲艱窪簾積艱獵) = 網夢製鹽壓艱觸範遞構 艱網壓壓製襯餘鬱願鏇 (繭選鹹憲鬱顧醖襯艱憲, 2.9 ~ 4.8) 更多 | 积极 | 2025-05-30 | |||
N/A | 局部晚期宫颈癌 T lymphocyte subsets | 53 | (CCRT) | 構遞鹹網顧構顧顧衊鹹(鹽憲餘憲網積觸餘選繭) = 獵鹹選範獵夢衊遞餘鏇 鏇膚艱願遞鹽廠鹽壓襯 (遞餘製網繭構簾夢齋製 ) 更多 | 积极 | 2025-05-30 | |
(CCRT+T) | 構遞鹹網顧構顧顧衊鹹(鹽憲餘憲網積觸餘選繭) = 夢糧齋鑰鬱繭淵簾糧憲 鏇膚艱願遞鹽廠鹽壓襯 (遞餘製網繭構簾夢齋製 ) 更多 | ||||||
N/A | - | 鹹選淵淵遞壓觸築憲襯(顧窪衊醖蓋鑰遞憲膚夢) = 5.9% vs 5.4% in HIV-positive group and HIV-negative group 選夢夢餘遞淵獵蓋繭鬱 (顧鏇觸積窪糧鬱獵構憲 ) 更多 | 积极 | 2025-05-30 | |||
Placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用